Morgan Stanley Maintains Overweight on CG Oncology, Raises Price Target to $117

Benzinga · 4d ago
Morgan Stanley analyst Jeffrey Hung maintains CG Oncology (NASDAQ:CGON) with a Overweight and raises the price target from $102 to $117.